Both have unique Oncology products. Geron's innovations and successes with telemeres fits well with Celgene's established products and their deep pockets. I believe this is a likely combination, since Celgene is looking for diversification.
"Imetelstat (GRN163L) is a potent and specific inhibitor of telomerase currently in clinical development as a potential therapeutic agent for the treatment of solid tumor and hematological malignancies. This first-in-class compound is a specially designed and modified oligonucleotide, which targets and binds directly to the active site of telomerase with high affinity. The proprietary oligonucleotide chemistry and lipid modification improves binding affinity and stability, and enables good cellular and tissue penetration, even at lower concentrations."
Celgene maintains continuing interst in Ongology & Telemeres
Now that the potential for "telemere therapy" has been established, one of the major drug companies will take a big part of the company, perhaps all of it. Geron means "pipeline", and for Celgene this means new products in "medicine of the future".
I believe that telemeres are dlose to the "holy grail" of modern medicine and cancer research.. Geron is the first with a breakthrough, and may be the most rewarded by the medical community and the investment community. I am surprised that the stock is still so low.
Celgene has a market cap of 42 billion. It's interesting that Geron's Imetelstat in Phase II clinical trial is for Multiple myeloma, While presently Celgene has THALOMID used in combination with dexamethasone for patients with newly diagnosed multiple myeloma.
Perhaps a combo of Thalomid, Imetelstat, and Dexamethasone might be worth look at by Celgene.